Chemistry:Iomeprol
From HandWiki
Iomeprol, sold under the brand name Imeron among others, is a medication used as a radiocontrast agent in X-ray imaging.[1][2][3]
Iomeprol was approved for medical use in the United States in November 2024.[1][4][5]
Side effects
It is classified as a water-soluble, nephrotrophic, low osmolar X-ray contrast medium.[2] Low osmolar non-ionic agents are better tolerated and less likely to cause side effects than the high osmolar ionic agents.[2]
Society and culture
Iomeprol is not metabolized in the human body but excreted in unchanged form. It is decomposed slowly and can therefore accumulate in the environment.[6]
Legal status
Iomeprol was approved for medical use in the United States in November 2024.[1][4]
Brand names
Iomeprol is sold under the brand name Iomervu.[1]
References
- ↑ 1.0 1.1 1.2 1.3 Cite error: Invalid
<ref>tag; no text was provided for refs namedIomervu FDA label - ↑ 2.0 2.1 2.2 South African medicines formulary (11th ed.). Rondebosch, South Africa: Health and Medical Pub. Group .of the South African Medical Association. 2014. ISBN 978-1-875098-30-9. OCLC 869772940.
- ↑ (in German) Austria-Codex. Vienna: Österreichischer Apothekerverlag. 2020. Iomeron 300 mg J/ml-Infusionsflasche.
- ↑ 4.0 4.1 "Novel Drug Approvals for 2024". 1 October 2024. https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024.
- ↑ (PDF) New Drug Therapy Approvals 2024 (Report). January 2025. https://www.fda.gov/media/184967/download. Retrieved 21 January 2025.
- ↑ "IC-ICP/MS-Analytik" (in de). GIT Labor-Fachzeitschrift: 29–31. January 2015.
 |  |
